ICMJE DISCLOSURE FORM

Date: 2021/4/22
Your Name: Kosuke Sakai

Manuscript Title: Initial rapidity of tumor growth as a prognostic factor for the therapeutic effect of immune-checkpoint inhibitors in patients with non-small cell lung cancer: evaluation for linear and non-linear correlation
Manuscript number (if known): 

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. “Related” means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author’s relationships/activities/interests as they relate to the current manuscript only.

The author’s relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

|   | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------|
| **Time frame: Since the initial planning of the work** |                                                                                   |                                                                                  |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | None                                                                             |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | None                                                                             |
| 3 | Royalties or licenses | None                                                                             |
| 4 | Consulting fees | None                                                                             |
| **Time frame: past 36 months** |                                                                                   |                                                                                  |
|   | Description                                                                 | Answer |
|---|------------------------------------------------------------------------------|--------|
| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | None   |
| 6 | Payment for expert testimony                                               | None   |
| 7 | Support for attending meetings and/or travel                               | None   |
| 8 | Patents planned, issued or pending                                         | None   |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board           | None   |
|10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | None   |
|11 | Stock or stock options                                                      | None   |
|12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services | None   |
|13 | Other financial or non-financial interests                                  | None   |

**Please summarize the above conflict of interest in the following box:**











**Please place an “X” next to the following statement to indicate your agreement:**

_X_ I certify that I have answered every question and have not altered the wording of any of the questions on this form.
ICMJE DISCLOSURE FORM

Date: 2021/4/23
Your Name: Joji Kuramoto

Manuscript Title: Initial rapidity of tumor growth as a prognostic factor for the therapeutic effect of immune-checkpoint inhibitors in patients with non-small cell lung cancer: evaluation for linear and non-linear correlation

Manuscript number (if known): _______________________________________________________

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. “Related” means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author’s relationships/activities/interests as they relate to the current manuscript only.

The author’s relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

| # | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|-------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------|
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) | **No time limit for this item.** |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | **None** |
| 3 | Royalties or licenses | **None** |
| 4 | Consulting fees | **None** |

Time frame: Since the initial planning of the work

Time frame: past 36 months
|   | Description                                                                 | Response |
|---|-----------------------------------------------------------------------------|----------|
| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | None     |
| 6 | Payment for expert testimony                                                | None     |
| 7 | Support for attending meetings and/or travel                                | None     |
| 8 | Patents planned, issued or pending                                          | None     |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board           | None     |
| 10| Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | None     |
| 11| Stock or stock options                                                      | None     |
| 12| Receipt of equipment, materials, drugs, medical writing, gifts or other services | None     |
| 13| Other financial or non-financial interests                                  | None     |

Please summarize the above conflict of interest in the following box:





Please place an “X” next to the following statement to indicate your agreement:

**X** I certify that I have answered every question and have not altered the wording of any of the questions on this form.
ICMJE DISCLOSURE FORM

Date: 2021/4/23
Your Name: Hiroaki Nishimura

Manuscript Title: Initial rapidity of tumor growth as a prognostic factor for the therapeutic effect of immune-checkpoint inhibitors in patients with non-small cell lung cancer: evaluation for linear and non-linear correlation

Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. “Related” means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author’s relationships/activities/interests as they relate to the current manuscript only.

The author’s relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

|   | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|-------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------|
| 1 | **All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)**<br><b>No time limit for this item.</b> | **None**<br>____________________________________________________________________________________________________________________________________________________|

**Time frame: Since the initial planning of the work**

|   | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|-------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------|
| 2 | **Grants or contracts from any entity (if not indicated in item #1 above).**<br><b>Time frame: past 36 months</b> | **None**<br>____________________________________________________________________________________________________________________________________________________|
| 3 | **Royalties or licenses**<br><b>Time frame: past 36 months</b> | **None**<br>____________________________________________________________________________________________________________________________________________________|
| 4 | **Consulting fees**<br><b>Time frame: past 36 months</b> | **None**<br>____________________________________________________________________________________________________________________________________________________|
|   | Conflict of Interest                                                                 | Answer |
|---|--------------------------------------------------------------------------------------|--------|
|  5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | None   |
|  6 | Payment for expert testimony                                                        | None   |
|  7 | Support for attending meetings and/or travel                                         | None   |
|  8 | Patents planned, issued or pending                                                  | None   |
|  9 | Participation on a Data Safety Monitoring Board or Advisory Board                    | None   |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | None   |
| 11 | Stock or stock options                                                               | None   |
| 12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services     | None   |
| 13 | Other financial or non-financial interests                                           | None   |

Please summarize the above conflict of interest in the following box:





Please place an “X” next to the following statement to indicate your agreement:

___ X I certify that I have answered every question and have not altered the wording of any of the questions on this form.
**ICMJE DISCLOSURE FORM**

**Date:** 2021/4/23  
**Your Name:** Yoshiki Kuwabara

**Manuscript Title:** Initial rapidity of tumor growth as a prognostic factor for the therapeutic effect of immune-checkpoint inhibitors in patients with non-small cell lung cancer: evaluation for linear and non-linear correlation

**Manuscript number (if known):**

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. “Related” means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author’s relationships/activities/interests as they relate to the current manuscript only.

The author’s relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

|   | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------|
| 1 | **Time frame: Since the initial planning of the work**  
All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  
**No time limit for this item.** | ____None |
| 2 | **Time frame: past 36 months**  
Grants or contracts from any entity (if not indicated in item #1 above). | ____None |
| 3 | Royalties or licenses | ____None |
| 4 | Consulting fees | ____None |
|   | Description                                                                 | Response |
|---|----------------------------------------------------------------------------|----------|
| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | None     |
| 6 | Payment for expert testimony                                               | None     |
| 7 | Support for attending meetings and/or travel                               | None     |
| 8 | Patents planned, issued or pending                                          | None     |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board           | None     |
| 10| Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | None     |
| 11| Stock or stock options                                                      | None     |
| 12| Receipt of equipment, materials, drugs, medical writing, gifts or other services | None     |
| 13| Other financial or non-financial interests                                  | None     |

Please summarize the above conflict of interest in the following box:




Please place an “X” next to the following statement to indicate your agreement:

_x_ I certify that I have answered every question and have not altered the wording of any of the questions on this form.
ICMJE DISCLOSURE FORM

Date: 2021/4/23
Your Name: Akitoshi Kojima
Manuscript Title: Initial rapidity of tumor growth as a prognostic factor for the therapeutic effect of immune-checkpoint inhibitors in patients with non-small cell lung cancer: evaluation for linear and non-linear correlation
Manuscript number (if known): __________________________________________________________

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. “Related” means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author’s relationships/activities/interests as they relate to the current manuscript only.

The author’s relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

| Time frame: Since the initial planning of the work |
|-----------------------------------------------|
| 1 All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
| 2 Grants or contracts from any entity (if not indicated in item #1 above). | None |
| 3 Royalties or licenses | None |
| 4 Consulting fees | None |

| Time frame: past 36 months |
|-----------------------------|
| 2 Grants or contracts from any entity (if not indicated in item #1 above). | None |
| 3 Royalties or licenses | None |
| 4 Consulting fees | None |
|   | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | None |
|---|-------------------------------------------------------------------------------------------------|------|
| 6 | Payment for expert testimony                                                                   | None |
| 7 | Support for attending meetings and/or travel                                                    | None |
| 8 | Patents planned, issued or pending                                                               | None |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board                                | None |
| 10| Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | None |
| 11| Stock or stock options                                                                         | None |
| 12| Receipt of equipment, materials, drugs, medical writing, gifts or other services                 | None |
| 13| Other financial or non-financial interests                                                       | None |

Please summarize the above conflict of interest in the following box:




Please place an “X” next to the following statement to indicate your agreement:

__x__ I certify that I have answered every question and have not altered the wording of any of the questions on this form.
ICMJE DISCLOSURE FORM

Date: 2021/4/23
Your Name: Maiko Sasaki-Toda

Manuscript Title: Initial rapidity of tumor growth as a prognostic factor for the therapeutic effect of immune-checkpoint inhibitors in patients with non-small cell lung cancer: evaluation for linear and non-linear correlation

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. “Related” means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author’s relationships/activities/interests as they relate to the current manuscript only.

The author’s relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

|   | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|-------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------|
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) | ____None                                                                            |
|   | **No time limit for this item.**                                                                |                                                                                    |

Time frame: Since the initial planning of the work

|   | Grant or contracts from any entity (if not indicated in item #1 above).  | ____None                                                                            |
|---|--------------------------------------------------------------------------|-------------------------------------------------------------------------------------|
| 2 | Royalties or licenses                                                    | ____None                                                                            |
| 3 | Consulting fees                                                         | ____None                                                                            |

Time frame: past 36 months
|   | Conflict of Interest Description                                                                 | Answer |
|---|------------------------------------------------------------------------------------------------|--------|
| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | None   |
| 6 | Payment for expert testimony                                                                 | None   |
| 7 | Support for attending meetings and/or travel                                                  | None   |
| 8 | Patents planned, issued or pending                                                            | None   |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board                             | None   |
|10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | None   |
|11 | Stock or stock options                                                                       | None   |
|12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services              | None   |
|13 | Other financial or non-financial interests                                                    | None   |

Please summarize the above conflict of interest in the following box:





Please place an “X” next to the following statement to indicate your agreement:

**x** I certify that I have answered every question and have not altered the wording of any of the questions on this form.
ICMJE DISCLOSURE FORM

Date: 2021/4/23
Your Name: Yumiko Ogawa-Kobayashi

Manuscript Title: Initial rapidity of tumor growth as a prognostic factor for the therapeutic effect of immune-checkpoint inhibitors in patients with non-small cell lung cancer: evaluation for linear and non-linear correlation

Manuscript number (if known): ______________________________________________________________________

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. “Related” means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author’s relationships/activities/interests as they relate to the current manuscript only.

The author’s relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

|   | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------|
| **Time frame: Since the initial planning of the work** |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  
**No time limit for this item.** | ____None |
| **Time frame: past 36 months** |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | ____None |
| 3 | Royalties or licenses | ____None |
| 4 | Consulting fees | ____None |
|   | Description                                                                 | Answer |
|---|-----------------------------------------------------------------------------|--------|
| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | None   |
| 6 | Payment for expert testimony                                                | None   |
| 7 | Support for attending meetings and/or travel                                | None   |
| 8 | Patents planned, issued or pending                                          | None   |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board           | None   |
|10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | None   |
|11 | Stock or stock options                                                      | None   |
|12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services | None   |
|13 | Other financial or non-financial interests                                  | None   |

Please summarize the above conflict of interest in the following box:


Please place an “X” next to the following statement to indicate your agreement:

___x  I certify that I have answered every question and have not altered the wording of any of the questions on this form.
ICMJE DISCLOSURE FORM

Date: 2021/4/23
Your Name: Satoshi Kikuchi

Manuscript Title: Initial rapidity of tumor growth as a prognostic factor for the therapeutic effect of immune-checkpoint inhibitors in patients with non-small cell lung cancer: evaluation for linear and non-linear correlation

Manuscript number (if known): _____________________________________________________________________

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. “Related” means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author’s relationships/activities/interests as they relate to the current manuscript only.

The author’s relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

|   | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|-------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------|
|1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) | None |
|   | No time limit for this item.                                                                    |                                                                                  |

|   | Time frame: Since the initial planning of the work                                              |                                                                 |
|---|-------------------------------------------------------------------------------------------------|---|
|2 | Grants or contracts from any entity (if not indicated in item #1 above).                      | None |
|3 | Royalties or licenses                                                                           | None |
|4 | Consulting fees                                                                                 | None |

|   | Time frame: past 36 months                                                                     | |
|---|-------------------------------------------------------------------------------------------------|---|
|   |                                                                                                 |---|
|   | Conflict of Interest                                                                 | Answer |
|---|-------------------------------------------------------------------------------------|--------|
| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | None   |
| 6 | Payment for expert testimony                                                          | None   |
| 7 | Support for attending meetings and/or travel                                          | None   |
| 8 | Patents planned, issued or pending                                                    | None   |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board                     | None   |
| 10| Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | None   |
| 11| Stock or stock options                                                                | None   |
| 12| Receipt of equipment, materials, drugs, medical writing, gifts or other services      | None   |
| 13| Other financial or non-financial interests                                             | None   |

Please summarize the above conflict of interest in the following box:

Please place an “X” next to the following statement to indicate your agreement:

_x_ I certify that I have answered every question and have not altered the wording of any of the questions on this form.
ICMJE DISCLOSURE FORM

Date: 2021/4/23
Your Name: Yusuke Hirata

Manuscript Title: Initial rapidity of tumor growth as a prognostic factor for the therapeutic effect of immune-checkpoint inhibitors in patients with non-small cell lung cancer: evaluation for linear and non-linear correlation

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. “Related” means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author’s relationships/activities/interests as they relate to the current manuscript only.

The author’s relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

|   | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|----------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------|
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)<br><strong>No time limit for this item.</strong> | __None |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | __None |
| 3 | Royalties or licenses | __None |
| 4 | Consulting fees | __None |

Time frame: Since the initial planning of the work

Time frame: past 36 months
|   | Description                                                                 | Answer |
|---|-----------------------------------------------------------------------------|--------|
| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | None   |
| 6 | Payment for expert testimony                                                | None   |
| 7 | Support for attending meetings and/or travel                                 | None   |
| 8 | Patents planned, issued or pending                                          | None   |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board            | None   |
|10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | None   |
|11 | Stock or stock options                                                       | None   |
|12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services | None   |
|13 | Other financial or non-financial interests                                   | None   |

Please summarize the above conflict of interest in the following box:

Please place an “X” next to the following statement to indicate your agreement:

__x__ I certify that I have answered every question and have not altered the wording of any of the questions on this form.
ICMJE DISCLOSURE FORM

Date: 2021/4/23
Your Name: Yuriko Mikami-Saito

Manuscript Title: Initial rapidity of tumor growth as a prognostic factor for the therapeutic effect of immune-checkpoint inhibitors in patients with non-small cell lung cancer: evaluation for linear and non-linear correlation

Manuscript number (if known): _____________________________________________________________________

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. “Related” means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author’s relationships/activities/interests as they relate to the current manuscript only.

The author’s relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

|   | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|-------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------|
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) | None |
|   | **No time limit for this item.**                                                                 |                                                                                   |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above).                       | None |
| 3 | Royalties or licenses                                                                           | None |
| 4 | Consulting fees                                                                                 | None |

Time frame: Since the initial planning of the work

Time frame: past 36 months
|   | Conflict of Interest Description                                                                 | Response |
|---|-----------------------------------------------------------------------------------------------|----------|
| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | None     |
| 6 | Payment for expert testimony                                                                   | None     |
| 7 | Support for attending meetings and/or travel                                                   | None     |
| 8 | Patents planned, issued or pending                                                              | None     |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board                              | None     |
|10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | None     |
|11 | Stock or stock options                                                                         | None     |
|12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services               | None     |
|13 | Other financial or non-financial interests                                                      | None     |

Please summarize the above conflict of interest in the following box:

Please place an “X” next to the following statement to indicate your agreement:

__x__ I certify that I have answered every question and have not altered the wording of any of the questions on this form.
ICMJE DISCLOSURE FORM

Date: 2021/4/23
Your Name: Shintaro Mikami

Manuscript Title: Initial rapidity of tumor growth as a prognostic factor for the therapeutic effect of immune-checkpoint inhibitors in patients with non-small cell lung cancer: evaluation for linear and non-linear correlation

Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. “Related” means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author’s relationships/activities/interests as they relate to the current manuscript only.

The author’s relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

| Item | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|------|--------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------|
| 1    | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) | None |

No time limit for this item.

| Time frame: Since the initial planning of the work |
|----------------------------------------------------|
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | None |
| 3 | Royalties or licenses | None |
| 4 | Consulting fees | None |

| Time frame: past 36 months                       |
| No. | Description                                                                 | Answer |
|-----|-----------------------------------------------------------------------------|--------|
| 5   | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | None   |
| 6   | Payment for expert testimony                                                | None   |
| 7   | Support for attending meetings and/or travel                                 | None   |
| 8   | Patents planned, issued or pending                                          | None   |
| 9   | Participation on a Data Safety Monitoring Board or Advisory Board            | None   |
| 10  | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | None   |
| 11  | Stock or stock options                                                      | None   |
| 12  | Receipt of equipment, materials, drugs, medical writing, gifts or other services | None   |
| 13  | Other financial or non-financial interests                                   | None   |

Please summarize the above conflict of interest in the following box:




Please place an “X” next to the following statement to indicate your agreement:

___x  I certify that I have answered every question and have not altered the wording of any of the questions on this form.
ICMJE DISCLOSURE FORM

Date: 2021/4/23

Your Name: Hiroyuki Kyoyama

Manuscript Title: Initial rapidity of tumor growth as a prognostic factor for the therapeutic effect of immune-checkpoint inhibitors in patients with non-small cell lung cancer: evaluation for linear and non-linear correlation

Manuscript number (if known): ______________________________________________________

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. “Related” means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author’s relationships/activities/interests as they relate to the current manuscript only.

The author’s relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

|   | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------|
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) | None                                                                              |
|   | **No time limit for this item.**                                                                 |                                                                                  |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above).                        | None                                                                              |
| 3 | Royalties or licenses                                                                          | None                                                                              |
| 4 | Consulting fees                                                                                | None                                                                              |
|   |                                                                 | None |
|---|-----------------------------------------------------------------|------|
| 5 | Payment or honoraria for lectures, presentations,               |      |
|   | speakers bureaus, manuscript writing or educational events      |      |
| 6 | Payment for expert testimony                                    |      |
| 7 | Support for attending meetings and/or travel                    |      |
| 8 | Patents planned, issued or pending                              |      |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board |      |
| 10| Leadership or fiduciary role in other board, society,           |      |
|   | committee or advocacy group, paid or unpaid                      |      |
| 11| Stock or stock options                                          |      |
| 12| Receipt of equipment, materials, drugs, medical writing, gifts  |      |
|   | or other services                                               |      |
| 13| Other financial or non-financial interests                       |      |

Please summarize the above conflict of interest in the following box:







Please place an “X” next to the following statement to indicate your agreement:

__x__ I certify that I have answered every question and have not altered the wording of any of the questions on this form.
**ICMJE DISCLOSURE FORM**

**Date:** 2021/4/23  
**Your Name:** Gaku Moriyama  

**Manuscript Title:** Initial rapidity of tumor growth as a prognostic factor for the therapeutic effect of immune-checkpoint inhibitors in patients with non-small cell lung cancer: evaluation for linear and non-linear correlation  

**Manuscript number (if known):** ______________________________________________________________________

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. “Related” means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author’s relationships/activities/interests as they relate to the current manuscript only.

The author’s relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

|   | Time frame: Since the initial planning of the work | Time frame: past 36 months |
|---|-------------------------------------------------|----------------------------|
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) | **None** |
|   | **No time limit for this item.** | |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | **None** |
| 3 | Royalties or licenses | **None** |
| 4 | Consulting fees | **None** |
### Conflict of Interest Form

| Question                                                                 | Answer |
|--------------------------------------------------------------------------|--------|
| Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | None   |
| Payment for expert testimony                                             | None   |
| Support for attending meetings and/or travel                             | None   |
| Patents planned, issued or pending                                       | None   |
| Participation on a Data Safety Monitoring Board or Advisory Board         | None   |
| Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | None   |
| Stock or stock options                                                   | None   |
| Receipt of equipment, materials, drugs, medical writing, gifts or other services | None   |
| Other financial or non-financial interests                                | None   |

**Please summarize the above conflict of interest in the following box:**









**Please place an “X” next to the following statement to indicate your agreement:**

- [x] I certify that I have answered every question and have not altered the wording of any of the questions on this form.
ICMJE DISCLOSURE FORM

Date: 2021/4/23
Your Name: Akihiko Gemma

Manuscript Title: Initial rapidity of tumor growth as a prognostic factor for the therapeutic effect of immune-checkpoint inhibitors in patients with non-small cell lung cancer: evaluation for linear and non-linear correlation

Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. “Related” means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author’s relationships/activities/interests as they relate to the current manuscript only.

The author’s relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

|   | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|-------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------|
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) | No time limit for this item. |
|   |                                                                                                  | Time frame: Since the initial planning of the work                                |
|   |                                                                                                  | ____ None                                                                          |
|   |                                                                                                  |                                                                                  |
|   |                                                                                                  |                                                                                  |
|   |                                                                                                  |                                                                                  |
|   |                                                                                                  |                                                                                  |
|   |                                                                                                  |                                                                                  |
|   |                                                                                                  |                                                                                  |
|   |                                                                                                  |                                                                                  |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above).                         | ____ None                                                                          |
| 3 | Royalties or licenses                                                                            | ____ None                                                                          |
| 4 | Consulting fees                                                                                  | ____ None                                                                          |

Time frame: past 36 months
|   | Description                                                                 | Companies/Names                                                                 |
|---|----------------------------------------------------------------------------|---------------------------------------------------------------------------------|
| 5 | Payment or honoraria for lectures, presentations, speakers bureaus,          | Bristol-Myers Squibb K.K | Chugai Pharmaceutical Co. Ltd.                                               |
|   | manuscript writing or educational events                                    | Daichi Sankyo Co. Ltd. | Kyorin Pharmaceutical Co., Ltd.                                             |
|   |                                                                              | AstraZeneca K.K.           | Ono Pharmaceutical Co. Ltd.                                                 |
|   |                                                                              | Eisai Co. Ltd.            | Nippon Boehringer Ingelheim Co. Ltd.                                       |
|   |                                                                              | Pfizer Japan Inc.        | TAIHO Pharmaceutical Co. Ltd.                                               |
| 6 | Payment for expert testimony                                                | None                                                                        |
| 7 | Support for attending meetings and/or travel                                | None                                                                        |
| 8 | Patents planned, issued or pending                                          | None                                                                        |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board           | None                                                                        |
| 10| Leadership or fiduciary role in other board, society, committee or advocacy  | None                                                                        |
|   | group, paid or unpaid                                                        |                                                                              |
| 11| Stock or stock options                                                       | None                                                                        |
| 12| Receipt of equipment, materials, drugs, medical writing, gifts or other      | None                                                                        |
|   | services                                                                     |                                                                              |
| 13| Other financial or non-financial interests                                   | None                                                                        |

Please summarize the above conflict of interest in the following box:

Akihiko Gemma reports receiving honoraria from Bristol-Myers Squibb K.K, Chugai Pharmaceutical Co. Ltd., Daichi Sankyo Co. Ltd., Kyorin Pharmaceutical Co., Ltd., AstraZeneca K.K., Ono Pharmaceutical Co. Ltd., Eisai Co. Ltd., Nippon Boehringer Ingelheim Co. Ltd., Pfizer Japan Inc. and TAIHO Pharmaceutical Co. Ltd.

Please place an “X” next to the following statement to indicate your agreement:

**x** I certify that I have answered every question and have not altered the wording of any of the questions on this form.
**ICMJE DISCLOSURE FORM**

**Date:** 2021/4/23  
**Your Name:** Kazutsugu Uematsu

**Manuscript Title:** Initial rapidity of tumor growth as a prognostic factor for the therapeutic effect of immune-checkpoint inhibitors in patients with non-small cell lung cancer: evaluation for linear and non-linear correlation

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. “Related” means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author’s relationships/activities/interests as they relate to the current manuscript only.

The author’s relationships/activities/interests should be **defined broadly**. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

|   | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------|
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) | **No time limit for this item.** |

**Time frame: Since the initial planning of the work**

|   |   |   |
|---|---|---|
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) | **None** |

**Time frame: past 36 months**

|   |   |   |
|---|---|---|
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | **None** |
| 3 | Royalties or licenses | **None** |
| 4 | Consulting fees | **None** |
|   | Question                                                                 | Answer |
|---|-------------------------------------------------------------------------|--------|
| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | None   |
| 6 | Payment for expert testimony                                            | None   |
| 7 | Support for attending meetings and/or travel                            | None   |
| 8 | Patents planned, issued or pending                                      | None   |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board       | None   |
| 10| Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | None   |
| 11| Stock or stock options                                                  | None   |
| 12| Receipt of equipment, materials, drugs, medical writing, gifts or other services | None   |
| 13| Other financial or non-financial interests                               | None   |

Please summarize the above conflict of interest in the following box:

Please place an “X” next to the following statement to indicate your agreement:

_x_ I certify that I have answered every question and have not altered the wording of any of the questions on this form.